Evaluating Eligibility Criteria Of The Strong-hf Trial For Patients In Real-world Setting, An Experience From An Advanced Heart Failure Program In A Tertiary Care Health System

The STRONG-HF trial has demonstrated that an intensive treatment strategy involving the rapid up-titration of guideline-directed medication therapy (GDMT) and close patient monitoring can significantly reduce the incidence of all-cause death or readmission for acute heart failure (AHF) within 180 days compared to standard care. Nonetheless, there are concerns regarding the trial's selection criteria potentially restricting the external validity of this study, which may result in only a smaller group of patients being eligible for this novel intensive treatment strategy.
Source: Journal of Cardiac Failure - Category: Cardiology Authors: Tags: 085 Source Type: research